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Numerous human genome instability syndromes,
including cancer, are closely associated with events
arising from malfunction of the essential recombi-
nase Rad51. However, little is known about how
Rad51 is dynamically regulated in human cells.
Here, we show that the breast cancer susceptibility
protein BRCA2, a key Rad51 binding partner, coordi-
nates the activity of the central cell-cycle drivers
CDKs and Plk1 to promote Rad51-mediated genome
stability control. The soluble nuclear fraction of
BRCA2 binds Plk1 directly in a cell-cycle- and CDK-
dependent manner and acts as a molecular platform
to facilitate Plk1-mediated Rad51 phosphorylation.
This phosphorylation is important for enhancing the
association of Rad51 with stressed replication forks,
which in turn protects the genomic integrity of prolif-
erating human cells. This study reveals an elaborate
but highly organized molecular interplay between
Rad51 regulators and has significant implications
for understanding tumorigenesis and therapeutic
resistance in patients with BRCA2 deficiency.
INTRODUCTION
Germline mutations in the breast cancer susceptibility gene
BRCA2 confer an elevated risk of breast, ovarian, and other can-
cers (Lancaster et al., 1996; Wooster et al., 1995), as well as
developmental defects, childhood brain tumors, and other solid
tumors in a subgroup of Fanconi anemia (FA-D1) patients
(Howlett et al., 2002). These human disorders linked to BRCA2
deficiency are thought to reflect the functions of BRCA2 in con-
trolling genome integrity, which are primarily mediated through
its binding to the Rad51 recombinase, an essential enzyme
that plays central roles in faithful repair of DNA double-strand
breaks (DSBs) and in protection of stressed replication forks
(Hashimoto et al., 2010; Petermann et al., 2010; West, 2003).CBRCA2 contains eight evolutionarily conserved Rad51-binding
BRC motifs, which facilitate the recruitment of Rad51 to sites
of DSBs and the subsequent stimulation of DSB repair by homol-
ogous recombination (HR) (Pellegrini and Venkitaraman, 2004).
Additionally, an unrelated Rad51 binding site within the BRCA2
C-terminal domain, termed the TR2 motif, plays a critical role
in assisting the Rad51-mediated protection of replication forks,
especially when DNA synthesis is stalled due to nucleotide
depletion, as happens following treatment with hydroxyurea
(HU), a potent ribonucleotide reductase inhibitor (Lomonosov
et al., 2003; Schlacher et al., 2011).
BRCA2 undergoes extensive phosphorylation by central
cell-cycle regulators such as cyclin-dependent kinases (CDKs)
(Esashi et al., 2005), suggesting that BRCA2 functions are
dynamically regulated during the cell cycle. In particular, CDK-
dependent phosphorylation at serine 3291 (S3291) within the
TR2 region switches the function of BRCA2 such that it contrib-
utes to the removal of residual Rad51 fromDNA as cells progress
into mitosis (Ayoub et al., 2009; Esashi et al., 2005). Additional
CDK-dependent phosphorylation sites have been identified in
the BRCA2 N- and C-terminal regions (Esashi et al., 2005),
although their molecular and physiological roles remain
unknown. BRCA2 is also known to be phosphorylated by polo-
like kinase 1 (Plk1) (Lee et al., 2004; Lin et al., 2003), a proto-
oncogene product that is well documented as a mitotic
regulator. Plk1 typically binds CDK-phosphorylated proteins
via its phospho-binding polo-box domain (PBD), and subse-
quently phosphorylates proteins locally at specific subcellular
structures or within the same complex (Barr et al., 2004; Bruin-
sma et al., 2012; Elia et al., 2003). Significantly, abundant evi-
dence indicates that Plk1 plays multiple cellular functions in
time and space through this mechanism, and contributes to
the control of not only mitosis but also DNA stress responses
and DNA replication (Bruinsma et al., 2012). BRCA2 has been
proposed to function closely with Plk1, but it remains unknown
whether Plk1 binds directly to BRCA2 and/or provides broader
functions in regulating other subunits of the BRCA2 complex to
maintain genome stability.
We recently found that Plk1 phosphorylates Rad51 at serine
14 (S14) within a structurally disordered part of the N-terminalell Reports 7, 1547–1559, June 12, 2014 ª2014 The Authors 1547
Figure 1. BRCA2 Interacts with Plk1
through ResiduesMutated in Breast Cancer
(A) WCEs from untreated or nocodazole (Noc)-
treated HeLa cells were used for IP with anti-Plk1
or control rabbit IgG, and coprecipitated BRCA2
was detected with BRCA2 antibody.
(B) Recombinant His-NTD was phosphorylated by
recombinant CDK2/cyclin A in vitro and the in-
teractions between Plk1-PBD and BRCA2 frag-
ments were detected by far-western blotting.
(C) BRCA2 domain architecture, highlighting BRC
motifs (black bars), oligonucleotide/oligosaccha-
ride binding (OB) folds (white blocks), and the TR2
motif (gray bar). Locations of minimal PBD-binding
sequences (asterisks) and the N-terminal BRCA2
fragment, NTD (purple bar) are shown. Bottom
panel shows multiple amino acid sequence align-
ment surrounding the PBD-binding motif within
the NTD. Breast cancer-associated mutations at
residues A75 and T77, and the putative Plk1-
binding region are also indicated. The reported
numbers of breast cancer patients (Breast Cancer
Information Core) are shown in brackets. Cl, dog;
Fc, cat; Bt, cattle; Hs, human; Pt, chimpanzee;
Mm,mouse; Rn, rat; Oa, platypus; Gg, chicken; Xt,
frog; Dr, fish.
(D) FLAG-tag or FLAG-BRCA2 NTD variants (WT,
T77A, and A75P) were transiently expressed in
HEK293T cells, and following treatment with no-
codazole, interaction with endogenous Plk1 was
analyzed by IP with Plk1 antibody.
(E) Schematic diagram of FLAG-EGFP (FE)-tag-
ged full-length BRCA2 variants, representing
FLAG (orange) and EGFP (green). An amino acid
substitution within the NTD (asterisk) that impairs
Plk1 interaction is also indicated.
(F) FE-BRCA2WT, T77A, A75P variants, or FE-tag were conditionally expressed in HEK293 Flp-In T-REx cells and treated with nocodazole, where indicated. The
association of the BRCA2 variants with an exogenously expressed GST fusion of Plk1 was detected following GST pull-down.
See also Figure S1.domain (Yata et al., 2012), which is connected by a flexible loop
to the central ATP-binding core domain. Phosphomimetic muta-
tion of Rad51 at S14 led to no detectable change in its binding to
BRCA2 (Yata et al., 2012) or to its ATP-dependent biochemical
properties as assessed in vitro by the formation of nucleoprotein
filament on single-stranded DNA (ssDNA) and by homologous
pairing and strand transfer reactions (F.E., unpublished data).
Instead, we found that this phosphorylation stimulates subse-
quent Rad51 phosphorylation at threonine 13 (T13) by an acido-
philic kinase, casein kinase 2 (CK2), which in turn facilitates
Rad51 accumulation at DNA damage sites through its phos-
pho-dependent interaction with the Nijmegen breakage
syndrome gene product Nbs1, a subunit of the MRN (Mre11-
Rad50-Nbs1) damage sensor complex. Strikingly, S14 phos-
phorylation transiently increases in response to DNA damage,
such as ionizing radiation (IR), and promotes efficient HR repair
of DSBs, but the mechanism by which damage-induced Rad51
phosphorylation is regulated remains unidentified.
In this study, we investigated the molecular link between
BRCA2-mediated and Plk1-mediated Rad51 regulation. Our
data provide evidence that CDK-mediated BRCA2 phosphoryla-
tion triggers binding of Plk1, which in turn phosphorylates Rad51
within the BRCA2 complex. Furthermore, using genome-wide1548 Cell Reports 7, 1547–1559, June 12, 2014 ª2014 The Authorschromatin immunoprecipitation sequencing (ChIP-seq), isola-
tion of proteins on nascent DNA (iPOND), and a single-molecule
DNA fiber technique, we demonstrate that Rad51 phos-
phorylation by Plk1 is important for replication fork stability.
This study uncovers an unexpected molecular mechanism by
which BRCA2 coordinates CDK and Plk1 activities to promote
Rad51-mediated maintenance of genome stability.
RESULTS
The BRCA2 N Terminus Interacts with Plk1 in
a CDK-Dependent Manner
In the course of our investigation into the regulation of BRCA2
during the cell cycle, we found an enhanced association
between BRCA2 and Plk1 in human cells following treatment
with nocodazole, an anti-tubulin reagent that arrests cells in
early mitosis with high CDK activity and is also known to pro-
voke substantial DNA stress after prolonged exposure (Fig-
ure 1A) (Dalton et al., 2007; Giunta et al., 2010; Quignon
et al., 2007). Furthermore, GFP pull-down analyses using
GFP fusions of nine overlapping BRCA2 fragments, which
together encompass the whole of BRCA2, revealed that Plk1
association is mediated through the N-terminal domain (NTD;
1–454, B2-1 fragment in Figure S1A) and the C-terminal
domain (CTD; 3,189–3,418, B2-9 fragment in Figure S1A), the
regions that are efficiently phosphorylated by recombinant
CDK2/cyclin A in vitro (Figure S1B; Esashi et al., 2005). In
line with these observations, we identified minimal Plk1 PBD-
binding motifs S-[pT/pS]-P with predicted CDK target residues
within the NTD (T77) and CTD (T3193, S3219, and T3242). In
particular, the T77-containing motif is distinctively conserved
among vertebrates and is a good match to the optimal PBD-
binding motif [P/F]-[4/P]-4-[T/Q/H/M]-S-[pT/pS]-[P/X], where
4 represents a hydrophobic amino acid (Figure S1C; Elia
et al., 2003). As predicted from the amino acid sequence, our
far-western blotting analyses confirmed a direct interaction be-
tween recombinant Plk1-PBD and a His-NTD fragment phos-
phorylated in vitro by CDK2/cyclin A, but not a His-NTD variant
with an alanine substitution at T77 (T77A; Figure 1B).
Breast Cancer Mutations at the PBD-Binding Site within
the BRCA2 NTD Abrogate Plk1 Interaction
Notably, T77A and A75P mutations within the NTD of BRCA2
have been reported in a number of breast cancer patients
(Breast Cancer Information Core Database, National Human
Genome Research Institute; Figure 1C). Hence, we next
examined whether these cancer-associated mutations affect
BRCA2-Plk1 interaction in vivo. Remarkably, in contrast to
wild-type (WT) FLAG-tagged BRCA2 NTD (FLAG-NTD), which
showed a strong in vivo interaction with endogenous Plk1, no
such association was detected for FLAG-NTD harboring a
T77A or A75P mutation (Figure 1D). We further assessed the
impact of a T77A or A75P mutation on the interaction between
full-length BRCA2 and Plk1 using cells that coexpress FLAG-
and EGFP-tagged BRCA2 (FE-BRCA2) variants and a GST
fusion of Plk1 (Figure 1E). Significantly, the association of
FE-BRCA2 bearing either a T77A or A75P mutation with
GST-Plk1 was largely impaired compared with WT FE-BRCA2
(Figure 1F), demonstrating that these residues within the
BRCA2 NTD may serve as the primary phospho-dependent
binding site for Plk1.
Encouraged by these findings, we next examined whether
BRCA2 is indeed phosphorylated at T77. A phospho-specific
antibody was raised against a BRCA2 peptide phosphorylated
at T77 (pT77) and the specificity of the pT77 antibody was veri-
fied by a peptide dot blot assay (Figure S2A). The pT77 anti-
body also detected BRCA2 NTD (Figure 2A) or full-length
BRCA2 phosphorylated with recombinant CDK2/cyclin A (Fig-
ure S2B), confirming that CDK2 directly phosphorylates T77
in vitro. To further assess T77 phosphorylation of BRCA2
in vivo, we affinity purified FLAG-NTD, FE-BRCA2, and their
T77A and A75P variants from human cells, and examined their
phosphorylation status using the pT77 antibody. The antibody
detected WT FLAG-NTD and FE-BRCA2, but not the T77A or
A75P variants, showing that the overexpressed NTD fragment
and full-length BRCA2 can be phosphorylated at T77 in vivo
(Figures S2C and 2B, respectively). These results demonstrate
that the cancer-associated T77A and A75P mutations block
phosphorylation at residue 77. Importantly, the pT77 antibody
also detected endogenous BRCA2 from HeLa cells, but not
from EUFA423 (FA-D1) fibroblasts, which express BRCA2Clacking the C-terminal 192 amino acids (Howlett et al., 2002),
or from the Capan-1 pancreatic cancer cell line, which has a
larger C-terminal deletion of 1,416 amino acids (Goggins
et al., 1996; Figures 2C and 2D). These observations suggest
that endogenous BRCA2 is phosphorylated at T77 in vivo,
but only in the full-length form.
We further assessed whether BRCA2 phosphorylation at T77
is indeed mediated by CDKs in vivo. To this end, HeLa cells
were treated with the CDK inhibitors RO-3306, which primarily
inhibits CDK1 (Vassilev et al., 2006), or NU6102, which inhibits
CDK1 and CDK2 with comparable potency (Davies et al.,
2002). pT77 levels were reduced in cells treated with either
CDK inhibitor, with a greater reduction following NU6102 treat-
ment, suggesting that BRCA2 T77 is phosphorylated by both
CDKs in vivo (Figure 2E). Analysis of synchronized HeLa cells
further revealed that T77-phosphorylated BRCA2 (pT77-
BRCA2) increased in abundance as cells progressed into
mitosis, closely resembling the timing of BRCA2 phosphorylation
at S3291 (pS3291-BRCA2) (Figures 2F, 2G, S2D, and S2E) (Esa-
shi et al., 2005). To our surprise, however, pS3291-BRCA2 was
barely detectable in the Rad51 immunocomplexes from the sol-
uble fraction (Figure S2D), suggesting that an as-yet-unknown
mechanism may interfere with Rad51 binding to the pool of
endogenous BRCA2 that is physiologically phosphorylated at
S3291, despite the presence of additional Rad51-binding BRC
motifs in the middle region. In marked contrast, pT77-BRCA2
substantially retained Rad51 binding, and from late S phase to
mitosis formed a soluble complex containing Plk1 and Rad51
phosphorylated at both S14 and T13 (Figure 2F). Furthermore,
we observed that a complex containing pT77-BRCA2, Plk1,
and S14-phosphorylated Rad51 (pS14-Rad51) became abun-
dant in cells treated with nocodazole (Figure S2F), but was dis-
rupted following brief treatment with RO-3306 (Figure S2G).
Together, these data indicate that CDKs phosphorylate BRCA2
at T77 in a cell-cycle-dependent manner, leading to the forma-
tion of a protein complex containing Plk1, pS14-Rad51, and
pT13/pS14-Rad51.
BRCA2 Facilitates Plk1-Dependent Rad51
Phosphorylation
The finding of BRCA2, Plk1, and Rad51 in a common complex
(Figures 2F, S2D, S2F, and S2G) led us to explore the possibility
that BRCA2 may act as a core regulatory platform that brings
Plk1 and Rad51 into close proximity and, in this manner, pro-
motes Plk1-dependent Rad51 phosphorylation at S14 during
the cell cycle and/or following genotoxic stress. In line with this
idea, we found that BRCA2 interacts exclusively with Plk1 and
not with the other Plk family members Plk2 and Plk3, and that
the interaction with Plk1 is retained after DNA damage treatment
(Figures S2H and S2I). Furthermore, a cellular fractionation anal-
ysis of irradiated cells revealed that although pS14-Rad51 was
detectable in both the cytoplasmic and nuclear soluble fractions,
IR treatment induced a higher level of pS14-Rad51 specifically in
the nuclear soluble fraction, which contained the majority of
BRCA2 and Plk1 (Figure 3A, lanes 3 and 4). To investigate
whether BRCA2 is indeed involved in damage-induced Rad51
phosphorylation in vivo, we evaluated the level of pS14-Rad51
in two isogenic DLD1 cell lines, BRCA2+/ and BRCA2/, inell Reports 7, 1547–1559, June 12, 2014 ª2014 The Authors 1549
Figure 2. BRCA2 T77 Is Phosphorylated
In Vivo in a CDK-Dependent Manner
(A) Recombinant WT and T77A His-BRCA2 NTD
were phosphorylated in vitro with recombinant
CDK2/cyclin A, and phosphorylation at T77 was
assessed using pT77 phospho-specific antibody.
(B) Western blot analysis of partially purified
FE-BRCA2 WT, T77A, and A75P variants using
pT77 antibody.
(C) Schematic diagram of full-length BRCA2
showing mutations in Capan-1 and EUFA423 cells
indicated by dotted and solid arrows, respectively.
(D) Detection of pT77-BRCA2 in WCEs of HeLa,
EUFA423, and Capan-1.
(E) Detection of pT77-BRCA2 after treatment of
HeLa cells with CDK inhibitors, 10 mM RO-3306,
60 mM NU6102, or DMSO for 4 hr. Relative signal
intensities of pT77 in each sample were quantified
against the BRCA2 blot and are indicated under
each lane.
(F) Detection of pT77-BRCA2 in synchronized HeLa
cells using double thymidine block and release.
Rad51 complexes were immunoprecipitated from
the soluble fraction and analyzed using the indi-
cated antibodies. To monitor progression through
the cell cycle, chromatin-bound PCNA (S phase)
(Moldovan et al., 2007) and Histone H3 phosphor-
ylated at Serine 10 (pS10-H3; mitosis) (Hans
and Dimitrov, 2001) were detected. The asterisk
indicates a nonspecific band.
(G) Cell-cycle distribution analysis of propidium-
iodide-stained cells. As, asynchronous cells; Noc,
nocodazole-treated cells.
See also Figure S2.which respectively one or both BRCA2 alleles contain a prema-
ture stop codon after BRC repeat 5 (Hucl et al., 2008; Figure 3B).
Analogous to the data we obtained with HEK293T cells (Fig-
ure 3A), we found an IR-induced increase in pS14-Rad51 in the
nuclear soluble fraction from DLD1 BRCA2+/ cells (Figure 3C,
lanes 3 and 4). In contrast, no substantial increase was detect-
able in BRCA2/ cells, even with a higher level of Plk1
compared with DLD1 BRCA2+/ cells (Figure 3C, lanes 1 and
2). Similarly, pS14-Rad51 signal was reduced in BRCA2-defec-
tive EUFA423 cells and Capan-1 cells, or when endogenous
BRCA2 was downregulated using small hairpin RNA (shRNA) in
human cell lines (Figure S5F; K.Y. and F.E., unpublished data).
As BRCA2 deficiencies resulted in a reduction of pS14-Rad51,
we next asked whether elevated expression of BRCA2 would
conversely lead to an increase in Rad51 phosphorylation. Strik-
ingly, a higher level of pS14-Rad51 was detected in cells ex-
pressing WT FE-BRCA2 compared with cells expressing the1550 Cell Reports 7, 1547–1559, June 12, 2014 ª2014 The AuthorsFE tag only (Figures 3D and 3E, lanes 1
and 3), such that further IR induction of
pS14-Rad51 was obscured under these
conditions (data not shown). To further
assess the involvement of cell-cycle ki-
nases in regulating BRCA2 functions, we
treated these cells with nocodazole, which
imposes arrest in early mitosis with high
CDK and Plk1 activities, and genotoxicstress (Dalton et al., 2007; Giunta et al., 2010; Quignon et al.,
2007). Using this approach, we found an enhanced effect of
exogenous FE-BRCA2 expression on the induction of pS14-
Rad51 (Figure 3E, lanes 2 and 4).
In order to evaluate more directly whether BRCA2 interaction
with Rad51 is important for Plk1-dependent Rad51 phosphory-
lation, we generated full-length BRCA2 variants with mutations
that impair Rad51 binding through either BRC motifs or the
C-terminal TR2 (Figures 3D and S3). Such mutations were iden-
tified based on the crystal structure of the Rad51-BRC complex
and previously reported biochemical studies (Esashi et al., 2005;
Lo et al., 2003; Ochiai et al., 2011; Pellegrini et al., 2002; Rajendra
and Venkitaraman, 2010) (Figure S3). As expected, mutations
within BRC repeats 1–4 led to a substantial reduction of Rad51
binding (Figure S3F, lane 8), whereas the S3291E substitution,
which hinders interaction between TR2 and Rad51, largely re-
tained Rad51 binding (Figure S3F, lane 9), likely mediated
Figure 3. BRCA2 Facilitates Plk1-Dependent
Rad51 Phosphorylation at S14
(A) HEK293T cells were treated with IR (4 Gy, 20min
recovery), and pS14-Rad51 from the indicated
cellular fractions was immunoprecipitated with
pS14 antibody and detected with Rad51 antibody.
Cyt, cytoplasmic soluble fraction; Nuc, nuclear
soluble fraction; Chr, chromatin-bound fraction.
(B) Schematic diagram of the BRCA2 alleles in DLD1
BRCA2/ and BRCA2+/ cells.
(C) Endogenous Rad51 was immunoprecipitated
fromDLD1 BRCA2/ or BRCA2+/ cells before and
after irradiation (4 Gy). Thirty minutes after IR
treatment, nuclear soluble fraction was prepared
and pS14 was detected as in Figure 3A.
(D) Schematic diagram of FE-BRCA2 variants as
shown in Figure 1E. Amino acid substitutions within
the BRC (red asterisks and bars) and TR2 motifs
(blue asterisk and bar) that impair Rad51 interaction
are also indicated.
(E) FE-tag, FE-BRCA2 WT, BRC, TR2, or BRC/TR2
variants were conditionally expressed in HEK293
Flp-In T-REx cells and the level of S14 phosphoryla-
tion was assessed by IP with pS14-Rad51 antibody.
(F)As inFigure3E,BRCA2variantswereconditionally
expressed in HEK293 Flp-In T-REx cells, and the
level of S14 phosphorylation and association of
BRCA2 and Plk1 were assessed following Rad51 IP.
See also Figure S3.through the BRC motifs under this condition. Importantly, we
found that exogenous expression of FE-BRCA2 variants with
the BRC mutations and/or the TR2 mutation failed to increase
the level of pS14-Rad51 (Figure 3E, lanes 5–10). We also noticed
that although the BRCA2 variant with the TR2 mutation retained
Rad51 association, a relative reduction in the amount of pT77-
BRCA2 and BRCA2-associated Plk1 was seen following
Rad51 IP (Figure 3F, lanes 2 and 6). These observations support
the notion that BRCA2 indeed acts as a molecular platform to
facilitate Rad51 phosphorylation, and that appropriate interac-
tion among full-length BRCA2, Plk1, and Rad51 is critical for
this process.
pS14-Rad51 Accumulates at Sites of Broken DNA
Since Rad51 phosphorylation at S14 requires both the BRC and
TR2 motifs of BRCA2, we hypothesized that the cellular func-
tions of BRCA2 in Rad51-mediated genome integrity control,
namely, HR repair of DSBs and replication fork protection, are
brought about through its activity in facilitating Rad51 phosphor-
ylation by Plk1. In this scenario, the Rad51 S14 site would beCell Reports 7, 1547–15expected to be critical both for HR repair
and for protection of replication forks.
With regard to HR repair, Rad51 S14 has
been shown to play a physiologically
important role (Yata et al., 2012): S14
phosphorylation triggers subsequent
phosphorylation at T13 by CK2, which in
turn facilitates Rad51 binding to Nbs1,
hence promoting the recruitment of
Rad51 to broken DNA and HR repair ofDSBs (depicted in Figure 4A). The involvement of pS14-Rad51
in replication fork protection, however, has not previously been
addressed.
With this in mind, we assessed the genome-wide distribution
of phosphorylated Rad51 on chromatin in relation to DNA breaks
by ChIP-seq using Rad51 phospho-specific antibodies. In order
to introduce DSBs at defined genomic loci, we exploited U2OS
cells stably expressing a fusion of the AsiSI endonuclease with
the estrogen receptor ligand-binding domain (AsiSI-ER; Fig-
ure 4B; Iacovoni et al., 2010). The AsiSI-ER fusion normally
localizes to the cytoplasm, but translocates to the nucleus
upon treatment with 4-hydroxy tamoxifen (4-OHT), leading to
induction of DSBs at AsiSI sites across the genome (Figures
4C, S4A, and S4B). Significantly, we observed a broad accumu-
lation of pS14-Rad51 at induced DSB sites marked with gH2A.X
(Figures 4D, 4E, and S4C), along with more restricted pT13/
pS14-Rad51 binding, showing that Rad51 recruited to DSBs re-
tains phosphorylation. Notably, however, only a limited accumu-
lation of Plk1 was detectable at DSBs (Figure S4D), supporting
the idea that Rad51 is first phosphorylated at S14 in the soluble59, June 12, 2014 ª2014 The Authors 1551
(legend on next page)
1552 Cell Reports 7, 1547–1559, June 12, 2014 ª2014 The Authors
nuclear fraction (Figure 3A), followed by cooperative polymeriza-
tion on chromatin in the pS14 and pT13/pS14 forms.
pS14-Rad51 Accumulates at Stressed Replication Forks
Our ChIP-seq analysis identified pS14-Rad51 and pT13/pS14-
Rad51 peaks not only at DSB sites but also at distinct loci where
extensive gH2A.X peaks were not detectable (Figure 4D). Given
the role of Rad51 in replication fork protection (Hashimoto et al.,
2010; Petermann et al., 2010), we reasoned that these signals
may reflect association of phosphorylated Rad51 with stalled
DNA replication forks. To test this idea, we mapped at high res-
olution Rad51-binding sites in relation to nascent DNA genome
wide. Specifically, HeLa cells were treated with the thymidine
analog 5-bromo-2-deoxyuridine (BrdU) and aphidicolin, a potent
inhibitor of DNA polymerase a. Loci that had incorporated BrdU
were then isolated using a BrdU antibody and identified by next-
generation DNA sequencing. In agreement with our hypothesis,
pS14-Rad51 and pT13/pS14-Rad51 were detected in the
vicinity of BrdU incorporation regardless of the presence of
extensive gH2A.X signals (Figure 4F).
We further analyzed the dynamics of proteins that bound to the
nascent DNA following HU treatment using the iPOND method,
which allows sensitive detection of events associated with repli-
cation forks (Sirbu et al., 2012). It has been demonstrated that
HU treatment initially leads to stalled replication forks, which
eventually collapse into DSBs following prolonged HU exposure
(Petermann et al., 2010; Sirbu et al., 2011). In our iPOND ana-
lyses, nascent DNA was first pulse labeled with the thymidine
analog 5-ethynyl-20-deoxyuridine (EdU), and following exposure
to HU for increasing lengths of time, proteins associated with
labeled DNA were isolated and detected by western blotting
(Figure 5A). As shown in Figure 5B, HU treatment led to the rapid
removal of proliferating cell nuclear antigen (PCNA) from stalled
replication forks, while triggering H2A.X phosphorylation as a
consequence of checkpoint activation (Sirbu et al., 2011). In par-
allel, we found that Rad51 swiftly accumulated at replication
forks following HU treatment, whereas Nbs1 association with
the forks was mostly unaffected (Figure 5B). Strikingly, when
cells were treated with the Plk1 inhibitor BI 2536, reduced
Rad51 association with replication forks was readily detectable
in the absence of HU-induced stress (Figure 5C, lanes 3 and 4,
and S5A), and less efficient Rad51 recruitment and impaired
retention of Rad51 at HU-stalled replication forks were found
(Figure 5C, lanes 3–12). These observations suggest that Plk1
plays multiple roles to facilitate Rad51 association with replica-Figure 4. Phosphorylated Rad51 Accumulates at Sites of DSB and Rep
(A) Model showing sequential Rad51 phosphorylation mediated by Plk1 and CK2,
Nbs1.
(B) Depiction of DSBs induction at AsiSI sites across the genome using U2OS ce
(C) U2OS AsiSI-ER cells were treated with 0.3 mM 4-OHT for the indicated times
antibodies, respectively.
(D) Venn diagram representing the number of colocalizing peaks for pS14 and gH2
treated as in (C).
(E) Representative ChIP-seq profile of DNA-damage-responsive factors at a DSB
OHT for 4 hr. Arrowheads indicate locations containing the AsiSI target sequenc
(F) Representative ChIP-seq profile following replication stress within chromosom
DNA is labeled with the incorporation of BrdU.
See also Figure S4.
Ction forks during normal cell proliferation, as well as the recruit-
ment and retention of Rad51 at stressed replication forks.
To further assess whether Plk1 facilitates Rad51 association
with replication forks by phosphorylating S14, thus promoting
its interaction with Nbs1, we performed analogous experiments
using cells expressing a FLAG fusion of WT Rad51 or the S14A
nonphosphorylatable Rad51 variant (Yata et al., 2012). We
moderately downregulated endogenous Rad51 using shRNA
targeting the RAD51 30 UTR. Under these conditions, we found
a high level of exogenously expressed WT Rad51 at the replica-
tion forks in proliferating cells, and this association peaked at 2 hr
after HU treatment (Figures 5D and S5B). In contrast, we
observed a significantly lower level of fork-associated S14A
Rad51 compared with WT Rad51 (Figure 5D, lanes 2 and 8),
and the S14A form accumulated more slowly at HU-stalled
replication forks over the 4 hr of the time course (Figure 5D).
Importantly, Plk1 inhibitor treatment of these cell lines, which
moderately reduced S14 phosphorylation of WT FLAG-Rad51
(Figure S5C), advanced the peak of both WT and S14A Rad51
at stalled replication forks to 1 hr, followed by faster dissociation
at later time points (Figures 5E and S5D). These findings suggest
that Plk1-mediated Rad51 phosphorylation facilitates its
association at nonstressed replication forks and shortly after
HU treatment, but that the role of Plk1 in sustaining Rad51 at
stalled forks after prolonged HU treatment is independent of
S14 phosphorylation.
Our previous study suggested that unregulated Rad51 phos-
phorylation at S14, as found in cancer cells with a high level of
Rad51 or Plk1, bypasses BRCA2-mediated Rad51 recruitment
to sites of DNA damage, contributing to the resistance of
BRCA2-defective cancer cells to genotoxic stresses (Yata
et al., 2012). On the basis of this finding, we next investigated
the importance of BRCA2 in Rad51 association with replication
forks by downregulating BRCA2 (Figure S5E). With FLAG-
Rad51 expressed at a high level, we found that Plk1-mediated
Rad51 phosphorylation was indeed detectable, at a lower level,
after BRCA2 downregulation (Figure S5F), and that WT Rad51
was transiently recruited to HU-stalled replication forks (Fig-
ure 5F, lanes 2–6, and S5G). We also noticed that BRCA2 down-
regulation led to premature dissociation of WT Rad51 from
stalled replication forks 2–4 hr after HU treatment, likely reflect-
ing a previously described BRCA2 function by which it mechan-
ically stabilizes Rad51 nucleoprotein filaments (Schlacher
et al., 2011). Remarkably, extensive destabilization of Rad51
S14A at replication forks was found after HU treatment inlicative DNA
and recruitment of Rad51 to stressed DNA via phospho-dependent binding to
lls stably expressing HA-AsiSI-ER fusion (U2OS AsiSI-ER).
, and HA-AsiSI-ER and gH2A.X in WCEs were detected using HA and gH2A.X
A.X quantified from genome-wide ChIP-seq results, using U2OSAsiSI-ER cells
site within chromosome 17, 5–6 Mb, using U2OS AsiSI-ER cells treated with 4-
e (GCGATCGC).
e 6, 134–135 Mb, using HeLa cells treated with 5 mg/ml aphidicolin. Nascent
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BRCA2-depleted cells (Figure 5F, lanes 8–12). This observation
supports the notion that Plk1-mediated Rad51 phosphorylation
and BRCA2 have complementary functions in facilitating
Rad51 association with HU-induced stalled replication forks.
Rad51 S14 Is Important for Efficient Replication
Resumption
To further assess the impact of Plk1-dependent Rad51 phos-
phorylation in response to HU-induced replication stress, we
analyzed cellular phenotypes of U2OS cells stably expressing
exogenous WT Rad51 or the S14A variant, in which endogenous
Rad51 was downregulated with small interfering RNA (siRNA)
targeting the RAD51 30 UTR (Yata et al., 2012) (Figure 6A). Immu-
nofluorescence (IF) microscopy analysis showed, in both cell
lines, a similar increase in the number of gH2A.X foci following
HU treatment (Figures 6B and S6A). This observation is consis-
tent with the iPOND result showing that equivalent levels of
gH2A.X were induced at stalled replication forks of cells ex-
pressing either WT or S14A Rad51 (Figures 5D and S5B), and
indicates that Rad51 and its S14A variant have little impact on
either the replication checkpoint or the DNAdamage checkpoint.
Appropriate protection of stalled replication forks from
nascent DNA degradation facilitates efficient restart of replica-
tion when the obstacle is removed (Petermann et al., 2010;
Schlacher et al., 2011, 2012). We therefore examined the
involvement of Rad51 S14 in replication restart using the
single-molecule DNA fiber technique (Jackson and Pombo,
1998). Specifically, nascent DNA before and during recovery
from an HU-induced replication block was sequentially labeled
by incorporation of the thymidine analogs 5-iodo-20-deoxyuri-
dine (IdU) and 5-chloro-20-deoxyuridine (CldU), respectively
(Figure 6C). This analysis revealed that 50% of all DNA fibers
contained both IdU and CldU tracts in cells expressing WT
Rad51, whereas only 20% of fibers contained both tracts in
cells expressing S14A Rad51 (Figures 6D and S6B), suggesting
that a greater proportion of HU-stalled replication forks failed to
restart in cells expressing the S14A Rad51 mutant (Figure 6E). In
parallel, we noticed that there was no detectable difference be-
tween the cell lines with respect to the speed of DNA synthesis
during recovery from HU treatment, as evaluated from the length
of tracts or from the CldU/IdU tract ratio (Figures S6C and S6D).
These observations indicate that Rad51 S14 phosphorylation
promotes efficient resumption of replication after stress, but is
not involved in DNA synthesis once replication restarts. Impor-
tantly, we also observed significantly higher numbers of DNA
fibers containing only CldU tracts, which represent new originsFigure 5. S14 Is Important for Rad51 Accumulation at Replication Fork
(A) Depiction of the iPOND experimental procedure.
(B) Proteins associated with replication fork in HEK293T cells with or without 4
indicated antibodies. In order to discriminate proteins associated with DNA behin
containing a low concentration of thymidine (10 mM), and associated proteins we
(C) HEK293T cells were pretreated with 100 nM of Plk1 inhibitor BI 2536 for 30min
quantitation of one representative iPOND experiment, expressed as the relative
(D) HEK293 Flp-In T-REx cells conditionally expressing FLAG-tagged Rad51 WT
treated with HU, and proteins associated at nascent DNA were analyzed as in (B
(E) As in (D), except that cells were pretreated with BI 2536 for 30 min as in (C).
(F) As in (D), except that endogenous BRCA2 rather than Rad51 was downregula
See also Figure S5.
Cof replication, in cells expressing S14A Rad51 compared with
those expressing WT Rad51 (Figures 6F and S6B). Together,
these results suggest that although S14ARad51 is less proficient
than WT in promoting the resumption of ongoing DNA replica-
tion, new origins are activated to facilitate completion of S phase.
DISCUSSION
A growing body of evidence indicates that either insufficient or
excessive Rad51 activity leads to genome instability, which is
closely linked to cancer development and therapeutic resis-
tance. Despite its importance, surprisingly little is known about
the dynamic regulation of Rad51 during the cell cycle and in
response to genotoxic stress in human cells. Here, we provide
several lines of evidence that support a model in which BRCA2
coordinates the timely phosphorylation of Rad51 by Plk1, which
in turn facilitates Rad51 association both with DSBs and with
stalled replication forks and, through this mechanism, con-
tributes to the maintenance of genome integrity.
We have shown that Plk1 binding to BRCA2 is primarily medi-
ated through CDK-dependent phosphorylation at the evolution-
arily conserved T77 site. It has been technically challenging to
determine which CDK phosphorylates BRCA2 at T77 in vivo,
as CDK family members may play redundant functions when a
given CDK is dysfunctional (Murray, 2004). Nonetheless, T77
phosphorylation, which increases from late S phase and peaks
in mitosis, was efficiently blocked only when CDK1 and CDK2
were both inhibited, strongly suggesting these CDKs function
together to phosphorylate BRCA2 at this residue. Notably,
T77A and A75P mutations within the PBD-binding motif have
been reported in a number of breast cancer patients, indicating
a physiologically important role of the BRCA2-Plk1 interaction
in cancer prevention. Furthermore, in vivo phosphorylation of
endogenous BRCA2 at T77was detectable only in cells express-
ing full-length WT BRCA2, and not in BRCA2-defective cells,
including EUFA423 cells, which express an equivalent amount
of BRCA2 lacking only a short region of the CTD. These observa-
tions highlight the importance of full-length BRCA2 in coordi-
nating its appropriate phosphorylation and thus its protein com-
plex formation and associated functions. As has been suggested
elsewhere (Thorslund et al., 2010), it is conceivable that the CTD
of BRCA2 engages in a physical and/or functional interplay with
its NTD. In this context, it is tempting to speculate that CDKs that
associate with BRCA2 through cyclin-binding motifs within the
CTD (Esashi et al., 2005) might potentially be responsible for
BRCA2 phosphorylation within the NTD.s
mM of HU treatment were isolated by iPOND procedure, and detected with
d replication forks, EdU-labeled cells were subsequently incubated with media
re similarly detected (thymidine chase).
, followed by HU treatment and iPOND analysis as in (B). Right panel shows the
ratio of the total level of Rad51 against H2A.X.
or S14A, along with shRNA targeting the 30 UTR of endogenous RAD51, were
).
ted by shRNA.
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Figure 6. Rad51 S14 Is Important for Replication Restart after
Replication Stress
(A) Western blot analysis of U2OS cell lines expressing exogenous Rad51 WT
or S14A, after downregulation of endogenous Rad51 using siRNA targeting its
30 UTR.
(B) Percentage of HU-treated (4 mM for 4 hr) Rad51 WT and S14A U2OS cells
containing more than 20 gH2A.X foci. Error bars, SEM (n = 3).
(C) Illustration of the DNA fiber experimental setup, with incorporation of IdU
and CldU shown in red and green, respectively. Representative IF images of
DNA fibers defined as replication restart (incorporation of both IdU and CldU),
stalled replication fork (RF; IdU only), and new origin firing (CldU only) are
shown. The bar indicates 10 mm.
(D) Recovery of DNA synthesis was evaluated by the percentage of labeled
tracts containing both IdU and CldU against the total number of labeled tracts.
Error bars, SEM (n = 3).
(E) Stalled replication forks were evaluated by the percentage of labeled tracts
containing only IdU. Error bars, SEM (n = 3).
(F) Firing of new origins after HU treatment was evaluated by the percentage of
labeled tracts containing only CldU. Error bars, SEM (n = 3).
In panels (D)–(F), asterisks indicate unpaired two-tailed Student’s t test; ***p <
0.001, **p < 0.01. See also Figure S6.Our study also revealed that the level of Rad51 phosphoryla-
tion at S14 in the nuclear soluble fraction was largely dependent
on the presence of functional BRCA2, implying that BRCA2 in
this fraction has a distinctive role in facilitating Plk1-dependent
phosphorylation of Rad51. Our findings raise an interesting
question as to how Plk1 bound at the N-terminal region of
BRCA2 phosphorylates Rad51, which associates with the mid-
dle (BRC motifs) and the C-terminal (TR2) regions of BRCA2.1556 Cell Reports 7, 1547–1559, June 12, 2014 ª2014 The AuthorsAt present, it remains unknown how full-length BRCA2 folds
and associates with its binding partners in three dimensions.
Nonetheless, we speculate that the BRCmotifs might contribute
by presenting monomeric Rad51 in a manner that permits its
phosphorylation at S14 by Plk1. This idea is supported by previ-
ous observations that (1) the BRC motifs directly bind mono-
meric Rad51 through its central ATPase core domain (Pellegrini
et al., 2002); (2) residues between the BRC repeats, but not the
motifs themselves, are targeted by Plk1 (Lee et al., 2004); and
(3) Plk1-dependent BRCA2 phosphorylation does not interfere
with the BRCA2-Rad51 interaction (Lee et al., 2004; Lin et al.,
2003). We consider that the C-terminal TR2motif may contribute
to Plk1-mediated Rad51 phosphorylation differently from the
BRCmotifs. Rather than simply presenting Rad51 for phosphor-
ylation by Plk1 on a BRCA2 platform (as would be the case with
the BRC motifs), TR2 may modify the function of the N-terminal
region of BRCA2. This view is supported by our observation that
T77 phosphorylation levels were reduced in BRCA2 bearing a
TR2mutation or C-terminal truncation. TR2 would therefore indi-
rectly alter the Plk1 interaction with the N-terminal region of
BRCA2, leading to a reduced level of Rad51 phosphorylation
at S14. In parallel, we also noticed that although the total level
of pS14 was significantly reduced in cells expressing the
BRCA2 TR2 mutant, pS14-Rad51 was still detectable in the
complex containing this BRCA2 variant (K.Y., C.R., and F.E., un-
published data). These observations pose an alternative model
in which a TR2-mediated Rad51 interaction contributes to the
release of Rad51 from the BRC motif, providing an increased
pool of phosphorylated Rad51 that is free fromBRCA2; however,
further investigation will be required to evaluate this possibility.
In this study, we further demonstrated that the S14 residue in
Rad51 is important for protection of nascent DNA at stalled
replication forks following HU treatment. We also found that in
normally proliferating cells, Rad51 phosphorylation at S14, along
with formation of a complex containing Rad51, BRCA2, and
Plk1, takes place from late S phase to mitosis. This finding is
complementary to previous reports that Rad51 is dispensable
for the completion of bulk DNA replication but is essential in
G2 for entry intomitosis (Su et al., 2008), and that Rad51 protects
ssDNA gaps left behind replication forks from Mre11-mediated
degradation (Hashimoto et al., 2010). In earlier work, we showed
that phosphorylation of Rad51 at S14 triggers T13 phosphoryla-
tion, which then stimulates direct binding of the Nbs1 subunit of
the MRN complex (Yata et al., 2012). Of note, Nbs1 was recently
shown to protect genomic integrity in unperturbed cells during
G2 (Bruhn et al., 2014). We therefore envisage that Plk1-medi-
ated Rad51 phosphorylation provides a universal mechanism
to initiate Nbs1-mediated Rad51 recruitment to stressed or frag-
ile DNA to which the MRN complex is bound, including damaged
DNA, stalled replication forks, and postreplicative ssDNA. In this
way, completion of DNA repair and replication are ensured
before a higher level of chromosome condensation takes place
in mitosis, thus ensuring the protection of genome integrity.
The role described here for BRCA2 in facilitating Plk1-depen-
dent Rad51 phosphorylation might appear to be at odds with our
previous observation that Rad51 bypasses BRCA2 function in
HR repair, in a manner that is dependent on Plk1 phosphoryla-
tion at S14 (Yata et al., 2012). Indeed, we cannot exclude the
possibility that, together with BRCA2, additional factors may
help to coordinate the timely phosphorylation of Rad51 following
DNA stress. In support of this idea, we found that the pS14 signal
was reduced but still detectable in the absence of BRCA2. Also,
our iPOND analysis demonstrated that the association of Rad51
with replication forks was fully blocked only when both BRCA2
and Plk1-mediated phosphorylation of Rad51 at S14 were
defective. Furthermore, our analyses using ChIP-seq and iPOND
detected a partial association of Plk1 with some DSB sites and
replication forks. Notably, Plk1 has been shown to interact with
several DNA-damage-responsive proteins, such as MDC1,
53BP1, and SLX4 (Lowery et al., 2007; Svendsen et al., 2009;
van Vugt et al., 2010), and also with the MCM replication com-
plex at stalled replication forks (Song et al., 2011; Trenz et al.,
2008; Tsvetkov and Stern, 2005). Such factors, or elevated
Plk1 activity, which is found in many cancers, might be involved
in the resistance of BRCA2-defective cells to anticancer drugs
that induce DSBs or inhibit replication.
In summary, our work illuminates a dynamic and well-
coordinated molecular mechanism whereby the soluble nuclear
fraction of BRCA2 links the activities of CDKs and Plk1 to
facilitate Rad51-mediated genome stability control. This role of
BRCA2 is distinct from the previously demonstrated functions
of chromatin-associated BRCA2, which has been proposed to
recruit Rad51 directly to sites of stressed DNA. Our study has
important implications for understanding the spatiotemporal
functions of BRCA2 in proliferating human cells and howpatients
with BRCA2 deficiencies develop malignancy and therapeutic
resistance.
EXPERIMENTAL PROCEDURES
Mammalian Cell Culture
All mammalian cells were cultured at 37C with 5% CO2. HeLa, HEK293T,
U2OS, and EUFA423 cells were cultured in Dulbecco’s modified Eagle’s
medium containing streptomycin (0.1 mg/ml), penicillin (100 U/ml), and 10%
v/v fetal bovine serum. Capan-1 cells were maintained in the same medium,
with the addition of 20% v/v fetal bovine serum. DLD1 BRCA2+/ and DLD1
BRCA2/ cells (a kind gift from Dr. Scott Kern) were cultured in RPMI with
streptomycin (0.1 mg/ml), penicillin (100 U/ml), and 10% v/v fetal bovine
serum. HEK293 Flp-In T-REx FE-BRCA2 variant cell lines were maintained in
the same medium described above for HEK293T cells, supplemented with
15 mg/ml blasticidin (InvivoGen) and 50 mg/ml hygromycin (InvivoGen). Expres-
sion of full-length FE-BRCA2 variants was induced with 2 mg/ml doxycycline
for 48 hr prior to analyses. U2OS stable cell lines expressing Rad51 variants
were described previously (Yata et al., 2012). DNA transfection was carried
out using JetPRIME (Polyplus Transfection) following the manufacturer’s
protocols. Where indicated, cells were irradiated at 4 Gy with a 137Cs source
(Gravitron RX 30/55; Gravatom) or treated with 200 nM nocodazole (Sigma-
Aldrich) for 18 hr. For downregulation of endogenous proteins using siRNA,
cells were seeded at a density of 1.5–3 3 105 cells per well in six-well plate
format. On the next daywhen cells were attached on the plates, siRNAs target-
ing human Rad51 (siRad51) was transfected at a final concentration of 20 nM,
using DharmaFECT 1 (Dharmacon). Custom siRad51 was synthesized by
Sigma-Aldrich with the sequence provided in Table S1. For negative controls,
Mission siRNA Universal Negative Control #1 (SIC001; Sigma-Aldrich) was
used at final concentration of 20 nM. Following a further 24 hr incubation, cells
were harvested for analyses.
Antibodies
The antibodies used in this study are listed in Supplemental Experimental
Procedures. For pT77 antibody, a peptide (NH2)-CNQLAS(pT)PIIFK-(COOH)Ccoupled with KLH was used for rabbit immunization (Biogenes), and phos-
pho-specific antibody was purified as previously described (Yata et al., 2012).
ChIP-Seq Analyses
ChIP samples were prepared from U2OS cells stably expressing AsiSI-ER as
described previously (Deardorff et al., 2012; Iacovoni et al., 2010). DNA from
whole-cell extracts (WCEs) and ChIP fractions was sequenced on Applied
Biosystems SOLiD platforms (SOLiD 3 and 5500), and reads were aligned to
the human genome (UCSC hg19) using Bowtie as described previously (Dear-
dorff et al., 2012). The genome was scanned with a 3,000 bp sliding window
and peaks were identified by the following criteria: (1) fold enrichment
(IP reads / WCE reads) > 3, (2) a one-sided Wilcoxon rank-sum test
p value < 1 3 104, (3) IP intensity of peak summit / IP read average in
genome > 3, and (4) IP intensity of the peak summit bin > 4.0 per million reads
mapped for each chromosome. The data set is available from the National
Center for Biotechnology Information, Sequence Read Archive (NCBI-SRA;
http://www.ncbi.nlm.nih.gov/Traces/sra/).
Cell Treatment for iPOND
HEK293 Flp-In T-REx FLAG-Rad51 variant cell lines were cultured in
Dulbecco’s modified Eagle’s medium supplemented with streptomycin
(0.1 mg/ml), penicillin (100 U/ml), blasticidin (10 mg/ml; InvivoGen), hygromycin
B (100 mg/ml; InvivoGen), and 10% v/v fetal bovine serum. Expression of
FLAG-Rad51 WT and FLAG-Rad51 S14A was induced by addition of
2 mg/ml doxycycline (Sigma-Aldrich) overnight to 24 hr prior to iPOND exper-
iments. For endogenous Rad51 or BRCA2 knockdown, pSUPERIOR.puro
constructs expressing shRNA targeting human RAD51 mRNA 30 UTR or
human BRCA2 mRNA were respectively delivered to the cells 24 and 48 hr
before iPOND, using PEI transfection (Ehrhardt et al., 2006). Where indicated,
cells were treated with 100 nM Plk1 inhibitor BI 2536 (Axon Medchem) for
15 min before EdU labeling and throughout EdU labeling and HU chase. For
iPOND experiments, we adapted the procedures described in (Kliszczak
et al., 2011; Sirbu et al., 2012), with modifications described in Supplemental
Experimental Procedures.
IF and DNA Fiber Analysis
IF and DNA fiber analyses were carried out as previously described (Bleuyard
et al., 2012; Jackson and Pombo, 1998; Schwab et al., 2010), with modifica-
tions described in Supplemental Experimental Procedures.
ACCESSION NUMBERS
The NCBI-SRA accession numbers for the ChIP-seq data reported in this
paper are SRP040613 (Figures 4D, 4E, and S4D), SRP040614 (Figure 4F),
and SRP040615 (Figure S4C).
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